Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 12 Best Widow and Orphan Stocks to Buy According to Analysts.

Regeneron Pharmaceuticals Inc. (REGN) Reports Positive Results from Several Late-Stage Trials

On September 17, 2025, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported positive results from several late-stage trials, highlighting the strength of its pipeline beyond its core ophthalmology franchise. In its Phase 2 COURAGE obesity trial, the combination of semaglutide and trevogrumab reduced fat mass by up to 27.1%, compared to 15.7% for semaglutide monotherapy, while preserving significantly more lean muscle mass. Overall weight reduction ranged between 9.9% and 13.4% across treatment groups in the 599-patient study.

Additionally, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced that the monitoring committee recommended early crossover in its Phase 3 Optima trial of garetosmab for fibrodysplasia ossificans progressiva, after showing a 94% reduction in new bone lesions versus placebo. The company intends to expand Phase 3 testing to pediatric patients next year and submit a U.S. regulatory application for garetosmab by the end of 2025.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is a global pharmaceutical company that researches, develops, manufactures, and markets treatments for a wide range of diseases, including its EYLEA injection for severe retinal disorders. It is one of the Best Widow and Orphan Stocks.

While we acknowledge the potential of REGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than REGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Benefit From AI and 14 Best IT Stocks to Buy for the Long Term.

Disclosure: None.